Objectives: The primary objective of this study was to investigate the IL-1β levels in patients with inflammatory bowel disease, and to compare them to healthy controls. Subjects and methods: This cross-sectional cohort study enrolled a total of 100 subjects between May 2022 and January 2023 - 50 with inflammatory bowel disease alongside 50 healthy age-matched controls. Following an overnight fast, venepuncture was performed to obtain samples for baseline analyses and IL-1β concentration, which was determined using ProcartaPlex multiplex immunoassays. Results: A statically significantly higher concentration of IL-1β was identified in the IBD group compared to the control group (1.2±0.3 vs 0.38 ±0.12 pg/mL; P <0.001). Furthermore, higher hsCRP (1.9 ± 0.91. vs 0.98 ± 0.65 mg/L; P< 0.001), lower serum albumin (41.6 ± 5.2 vs 45.9 ± 3.8 g/L; P <0.001), and total cholesterol (5.3 ± 1.6 vs 4.7 ± 1.4 mmol/L; P = 0.047) among patients with IBD was noted. There was no significant difference in serum IL-1β concentration between patient with Crohn’s disease and patients with ulcerative colitis (1.18 ± 0.14 vs 1.14 ± 0.15 pg/mL; P = 0.864). Lastly, correlation analysis revealed serum concentrations of IL-1β positively correlated with both hsCRP (r = 0.322; P < 0.001) and calprotectin (r = 0.465; P < 0.001) in patients with IBD. Conclusions: IL-1β serum concentrations were increased in patients with IBD when compared with healthy controls. However, there was no significant difference in serum concentration of IL-1 β between patients with ulcerative colitis and Crohn's disease. Levels of hsCRP and faecal calprotectin positively correlated with serum IL-1β concentration in inflammatory bowel disease patients.